[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611031":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":269,"collaborators":271,"id":274,"slug":275,"hasResults":276,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":26,"eligibilityCriteria":280,"healthyVolunteers":276,"sex":281,"minAge":282,"maxAge":26,"enrollmentInfo":283,"targetDuration":26,"studyType":286,"phases":287,"briefSummary":289,"conditions":290,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},{"fullName":5,"class":6},"Kahr Medical","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DSP107 in combination with Atezolizumab","EXPERIMENTAL","DSP107 10 mg\u002Fkg IV on Days 1, 8, and 15 of each 28-day cycle. Atezolizumab 1680 mg IV on Day 1 of each 28-day cycle.",[13],"Drug: DSP107 + Atezolizumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Fruquintinib","ACTIVE_COMPARATOR","Participants will receive fruquintinib orally in 28-day cycles, for up to 24 cycles (96 weeks), or until disease progression, unacceptable toxicity, or study withdrawal.",[19],"Drug: Fruquintinib",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","DSP107 + Atezolizumab","DSP107 infusion begins \\~30 (±10) minutes after completion of atezolizumab infusion on Day 1.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"5 mg orally, once daily (with or without food), on Days 1-21 of each 28-day cycle, followed by 7 days off.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Adam Foley Comer","CONTACT","+972 54 749 1753","adam@kahrbio.com",[37,55,66,79,92,105,118,133,146,158,170,183,196,209,221,233,245,256],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP)","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-104.83192,39.72943,{"lat":49,"lon":48},[52],{"name":53,"role":54,"phone":26,"phoneExt":26,"email":26},"Hannah Robinson","PRINCIPAL_INVESTIGATOR",{"facility":56,"status":39,"city":57,"state":41,"zip":58,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"University of Colorado Cancer Center - Highlands Ranch Hospital","Highlands Ranch","80129",{"type":46,"coordinates":60},[61,62],-104.96943,39.55388,{"lat":62,"lon":61},[65],{"name":53,"role":54,"phone":26,"phoneExt":26,"email":26},{"facility":67,"status":39,"city":68,"state":69,"zip":70,"country":43,"countryCode":44,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Mayo Clinic","Florida City","Florida","32224",{"type":46,"coordinates":72},[73,74],-80.47922,25.44789,{"lat":74,"lon":73},[77],{"name":78,"role":54,"phone":26,"phoneExt":26,"email":26},"Conor O'Donnell, Dr",{"facility":80,"status":39,"city":81,"state":82,"zip":83,"country":43,"countryCode":44,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Duke University Medical Center - Duke Cancer Center","Durham","North Carolina","27710",{"type":46,"coordinates":85},[86,87],-78.89862,35.99403,{"lat":87,"lon":86},[90],{"name":91,"role":54,"phone":26,"phoneExt":26,"email":26},"Nicholas DeVito",{"facility":93,"status":39,"city":94,"state":95,"zip":96,"country":43,"countryCode":44,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"UPMC Hillman Cancer Center","Pittsburgh","Pennsylvania","15232",{"type":46,"coordinates":98},[99,100],-79.99589,40.44062,{"lat":100,"lon":99},[103],{"name":104,"role":54,"phone":26,"phoneExt":26,"email":26},"Anwaar Saeed, MD",{"facility":106,"status":39,"city":107,"state":108,"zip":109,"country":43,"countryCode":44,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"The University of Texas MD Anderson Cancer Center","Texas City","Texas","77030",{"type":46,"coordinates":111},[112,113],-94.9027,29.38385,{"lat":113,"lon":112},[116],{"name":117,"role":54,"phone":26,"phoneExt":26,"email":26},"Maria Pia Morelli, MD",{"facility":119,"status":39,"city":120,"state":121,"zip":122,"country":123,"countryCode":124,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"The Queen Elizabeth Hospital","Woodville","Adelaide","5011","Australia","AU",{"type":46,"coordinates":126},[127,128],138.54291,-34.877,{"lat":128,"lon":127},[131],{"name":132,"role":54,"phone":26,"phoneExt":26,"email":26},"Timothy Jay Price, Dr",{"facility":134,"status":39,"city":135,"state":136,"zip":137,"country":123,"countryCode":124,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Chris O'brien Lifehouse","Camperdown","New South Wales","2050",{"type":46,"coordinates":139},[140,141],151.17642,-33.88965,{"lat":141,"lon":140},[144],{"name":145,"role":54,"phone":26,"phoneExt":26,"email":26},"Sarah Isabella MacKenzie Sutherland, Dr",{"facility":147,"status":39,"city":148,"state":136,"zip":149,"country":123,"countryCode":124,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Port Macquarie Base Hospital (Mid North Coast Cancer Institute), Wrights Road,","Port Macquarie","2444",{"type":46,"coordinates":151},[152,153],152.90894,-31.43084,{"lat":153,"lon":152},[156],{"name":157,"role":54,"phone":26,"phoneExt":26,"email":26},"Dr Stephen Donald Begbie",{"facility":159,"status":39,"city":160,"state":136,"zip":161,"country":123,"countryCode":124,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Westmead Hospital","Westmead","2145",{"type":46,"coordinates":163},[164,165],150.98768,-33.80383,{"lat":165,"lon":164},[168],{"name":169,"role":54,"phone":26,"phoneExt":26,"email":26},"Adnan Mahmood Nagrial, Associate Professor",{"facility":171,"status":39,"city":172,"state":173,"zip":174,"country":123,"countryCode":124,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Icon Cancer Centre","South Brisbane","Queensland","4101",{"type":46,"coordinates":176},[177,178],153.02049,-27.48034,{"lat":178,"lon":177},[181],{"name":182,"role":54,"phone":26,"phoneExt":26,"email":26},"Jermaine lan George Coward, A\u002FProf",{"facility":184,"status":39,"city":185,"state":186,"zip":187,"country":123,"countryCode":124,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Flinders Medical Centre SA","Bedford Park","South Australia","5042",{"type":46,"coordinates":189},[190,191],138.56815,-35.02204,{"lat":191,"lon":190},[194],{"name":195,"role":54,"phone":26,"phoneExt":26,"email":26},"Christos Stelios Karapetis, Prof",{"facility":197,"status":39,"city":198,"state":199,"zip":200,"country":123,"countryCode":124,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"Monash Health","Clayton","Victoria","3168",{"type":46,"coordinates":202},[203,204],145.11667,-37.91667,{"lat":204,"lon":203},[207],{"name":208,"role":54,"phone":26,"phoneExt":26,"email":26},"David Kar Wah Lau, Dr",{"facility":210,"status":39,"city":211,"state":199,"zip":212,"country":123,"countryCode":124,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Footscray Hospital - Western Health","Footscray","3011",{"type":46,"coordinates":214},[215,216],144.9,-37.8,{"lat":216,"lon":215},[219],{"name":220,"role":54,"phone":26,"phoneExt":26,"email":26},"Peter Gibbs, Prof",{"facility":222,"status":39,"city":223,"state":199,"zip":224,"country":123,"countryCode":124,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Austin Health","Heidelberg","3084",{"type":46,"coordinates":226},[227,228],145.06667,-37.75,{"lat":228,"lon":227},[231],{"name":232,"role":54,"phone":26,"phoneExt":26,"email":26},"Niall Christopher Tebbutt, Prof",{"facility":234,"status":39,"city":235,"state":199,"zip":236,"country":123,"countryCode":124,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Alfred Hospital","Melbourne","3004",{"type":46,"coordinates":238},[239,240],144.96332,-37.814,{"lat":240,"lon":239},[243],{"name":244,"role":54,"phone":26,"phoneExt":26,"email":26},"Andrew Mark Meurisse Haydon, Dr",{"facility":246,"status":39,"city":247,"state":199,"zip":248,"country":123,"countryCode":124,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"Sunshine Hospital - Western Health","Saint Albans","3021",{"type":46,"coordinates":250},[251,252],144.8,-37.73333,{"lat":252,"lon":251},[255],{"name":220,"role":54,"phone":26,"phoneExt":26,"email":26},{"facility":257,"status":39,"city":258,"state":259,"zip":260,"country":123,"countryCode":124,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"Sir Charles Gairdner Hospital","Nedlands","Western Australia","6009",{"type":46,"coordinates":262},[263,264],115.8073,-31.98184,{"lat":264,"lon":263},[267],{"name":268,"role":54,"phone":26,"phoneExt":26,"email":26},"Rajiv Narayan Shinde, Dr",{"type":270,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[272],{"name":273,"class":6},"Novotech (Australia) Pty Limited","100611031","phase-2-a-study-to-test-dsp107-in-combination-with-atezolizumab-in-comparison-with-fruquintinib-as-a-new-treatment-for-colorectal-cancer-100611031",false,"NCT07235293","A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer","Inclusion Criteria:\n\n1. Are ≥ 18 years of age with a life expectancy of \\> 3 months.\n2. Participants with histologically confirmed, inoperable, MSS and\u002For pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy).\n3. Measurable disease per RECIST v1.1.\n\nExclusion Criteria:\n\n1. Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids.\n2. Unresolved AEs of Grade 2 or higher from prior anticancer therapy.\n3. Past or current history of autoimmune disease or immune deficiency.\n4. History of other malignancy within 3 years of first study treatment cycle.\n5. Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory).\n6. Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product.\n7. Clinically significant abnormal laboratory safety tests.","ALL","18 Years",{"count":284,"type":285},90,"ESTIMATED","INTERVENTIONAL",[288],"PHASE2","This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.",[291],"Colorectal Cancer","2026-08-19",{"date":294,"type":295},"2026-08-20","ACTUAL",{"date":297,"type":295},"2026-01-16",{"date":299,"type":285},"2027-04-30",{"name":301,"class":6},"Kahr Bio Australia Pty Ltd",18]